Author:
Melhus C. S.,Rivard M. J.,KurKomelis J.,Liddle C. B.,Massé F. X.
Publisher
Oxford University Press (OUP)
Subject
Public Health, Environmental and Occupational Health,Radiology, Nuclear Medicine and imaging,General Medicine,Radiation,Radiological and Ultrasound Technology
Reference35 articles.
1. Martin, R. C., Laxson, R. R., Miller, J. H., Wierzbicki, J. G., Rivard, M. J. and Marsh, D. L. Development of high-activity 252Cf sources for neutron brachytherapy. Appl. Radiat. Isot.48, 1567–1570 (1997).
2. Rivard, M. J., Kirk, B. L., Stapleford, L. J. and Wazer, D. E. A comparison of the expected costs of high dose rate brachytherapy using252Cf versus192Ir. Appl. Radiat. Isot.61, 1211–1216 (2004).
3. Maruyama, Y., Wierzbicki, J. G., Vtyurin, B. M. and Kaneta, K. Californium-252 neutron brachytherapy. In: Principles and Practice of Brachytherapy. Nag. S., Ed. (Armonk, NY: Futura Publishing Co., Inc.) pp. 649–687 (1997).
4. Maruyama, Y., Kryscio, R., Van Nagell, J. R., Yoneda, J., Donaldson, E., Hanson, M., Beach, J. L., Feola, J. M., Martin, A. and Parker, C. Clinical trial of 252Cf neutron brachytherapy vs. conventional radiotherapy for advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys.11, 1475–1482 (1985).
5. Tačev, T., Ptáčková, B. and Strnad, V. Californium-252 (252Cf) versus conventional gamma radiation in the brachytherapy of advanced cervical carcinoma. Strahlenther Onkol.179, 377–384 (2003).